Population Genetics

Mar 26, 2026 · 2 min read

Research Foundation: Redefining Ribosomal RNA

The Dogma

Human ribosomal RNA (rRNA) genes are the fundamental building blocks of ribosomes—the essential microscopic machineries responsible for translating proteins. For decades, the foundational sequences of these genes were considered universally conserved, or “untouchable,” with the assumption that they were identical across all human populations.

The Discovery

Driven by the need to understand how rRNA synthesis is altered in cancer, we undertook a massive bioinformatics analysis using whole-genome sequencing data from the 1000 Genomes Project. Analyzing 2,504 individuals across 26 distinct global populations, we uncovered a surprising twist: human rRNA genes exhibit widespread, ancestry-dependent genetic variation.

Key Findings: We identified 3,791 variant positions on the rRNA gene, including 470 distinct variants specifically located on the 28S rRNA segment—a critical component of the protein-translating ribosome.

Evolutionary Significance: Many of these variants are strongly segregated by geographic population, suggesting they are ancient, ancestry-dependent traits that have been evolutionarily retained due to their functional importance.

The Future: Implications for Cancer Therapeutics This discovery shatters the assumption of universally conserved human rRNA and opens an entirely new frontier in molecular biology. Because highly variable sites exist in the exact locations previously expected to be unaltered, the way variant rRNAs are built into ribosomes could significantly impact how those ribosomes function.

Building on this, our laboratory seeks to functionally assess how these 28S rRNA variants drive cancer development and therapeutic resistance. By understanding these diverse mechanisms, we aim to pave the way for highly targeted treatments, including the continued development and refinement of novel RNA Polymerase I inhibitors.

Wenjun Fan
Authors
Assistant Professor
Cancer biology researcher & targeted therapy developer